None listed
Conditions
Interventions
Drug : After oral administration of fexuprazan-based triple therapy (fexuprazan 40 mg twice a day, amoxicillin 1,000 mg 3 times a day, bismuth citrate potassium 300 mg 3 times a day) to Helicobacter p
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female between the ages of 20 and 80 2. A person diagnosed as positive for Helicobacter pylori in one of the urea breath test, rapid urease test, and biopsy 3. Patients with a history of atrophic gastritis, peptic ulcer, low-grade MALT lymphoma, functional dyspepsia, idiopathic thrombocytopenic purpura, iron-deficiency anemia, hyperproliferative polyp, past history of endoscopic resection for gastric cancer or gastric adenoma, or family history of gastric cancer 4. A person who agrees to participate in this test and voluntarily signs a written consent form
Exclusion criteria
Exclusion criteria: 1. Those who have undergone Helicobacter pylori eradication therapy prior to participation in the study 2. Those who have a history of hypersensitivity to the active ingredient or excipient of this clinical trial drug or penicillin-based antibiotics or macrolide-based antibiotics 3. Those who are taking contraindications to this clinical trial drug or concomitant drug 4. Proton pump inhibitors, histamine receptor antagonists, or potassium competitive gastric acid secretion inhibitors were taken for 2 weeks before the start of study drug administration, or proton pump inhibitors, histamine receptor antagonists, or potassium competitive gastric acid secretion inhibitors other than test drugs were taken until the end of the study participation period after randomization. Those who need to take 5. Those who have taken antibiotics or Bismuth within 4 weeks before upper gastrointestinal endoscopy and urea breath test, or who need to take antibiotics or Bismuth within 4 weeks before randomization and until the end of the study participation period after randomization 6. Patients with renal or hepatic impairment who show the following abnormal values ??in blood chemistry tests - AST, ALT, ALP, ?-GT, and total bilirubin levels are more than twice the upper limit reference value (UNL) for each test institution - BUN, creatinine levels are more than 1.5 times the upper limit reference value (UNL) for each test institution 7. Patients with central nervous system infection, electrolyte disorders (hypokalemia, hypomagnesemia) 8. In case of showing abnormal ECG results such as QT interval prolongation in screening ECG 9. Gastrointestinal bleeding during upper gastrointestinal endoscopy 10. Those with uncontrolled diabetes, high blood pressure, or liver dysfunction 11. A person with a history of malignant tumor of the digestive system within 5 years (except after endoscopic resection of gastric adenoma or early gastric cancer) 12. Those who have had esophageal or gastric resection 13. Subjects with genetic diseases such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 14. Alcoholics Anonymous 15. Those who do not agree to use the following appropriate methods of contraception for themselves or their partners during the clinical trial period ? Surgical infertility conditions: tubal ligation/tubectomy, hysterectomy, vasectomy/tubectomy, etc. ? Intrauterine device or intrauterine system ? Hormonal contraceptives: oral progesterone single or estrogen-progesterone combination, transdermal delivery contraceptives, depot injections, etc. ? Barrier method: Using a combination of male physical barrier methods (eg male condoms) and female physical barrier methods (eg female condoms, cervical cap, diaphragm, contraceptive sponge) together with spermicide Use (However, it is not recommended for both men and women to use condoms as they may be less effective than expected contraception due to damage caused by physical friction) However, women who are medically unable to conceive can participate in this clinical trial: women who have undergone menopause (24 months or more of amenorrhea), hysterectomy, salpingectomy, bilateral oophorectomy, etc. 16. Pregnant and lactating women 17. Persons judged by other researchers to be inappropriate to participate in clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate | — |
Secondary
| Measure | Time frame |
|---|---|
| medication adherence | — |
Countries
Korea, Republic of
Contacts
Public ContactJi Yong Ahn
Asan Medical Center
Outcome results
None listed